Reductive 17β-hydroxysteroid dehydrogenases in the sulfatase pathway: Critical in the cell proliferation of breast cancer

Molecular and Cellular Endocrinology

Volumn 301, Issue 1-2, 2009, Pages 183-190

  Aka, Juliette A ^a   Mazumdar, Mausumi ^a   Lin, Sheng Xiang ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

17 HSD1 inhibitors; Aromatase pathway; Breast cancer cell xenografts; Breast cancer cells; Reductive 17 hydroxysteroid dehydrogenases; Sulfatase pathway

Indexed keywords

AROMATASE; ESTROGEN; SULFATASE; TESTOSTERONE 17BETA DEHYDROGENASE; 3 (OR 17) BETA HYDROXYSTEROID DEHYDROGENASE; 3 (OR 17)-BETA-HYDROXYSTEROID DEHYDROGENASE; HYDROXYSTEROID DEHYDROGENASE;

BREAST CANCER; CANCER CELL CULTURE; CELL PROLIFERATION; HORMONE METABOLISM; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; ANIMAL; BREAST TUMOR; CHEMISTRY; ENZYMOLOGY; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY;

17-HYDROXYSTEROID DEHYDROGENASES; ANIMALS; AROMATASE; BREAST NEOPLASMS; CELL PROLIFERATION; HUMANS; OXIDATION-REDUCTION; SULFATASES;

EID: 60249089307     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.10.042     Document Type: Review

References (71)

1. Allan G.M., Lawrence H.R., Cornet J., Bubert C., Fischer D.S., Vicker N., Smith A., Tutill H.J., Purohit A., Day J.M., Mahon M.F., Reed M.J., and Potter B.V. Modification of estrone at the 6,16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 49 (2006) 1325-1345
2. Aspinall S.R., Stamp S., Davison A., Shenton B.K., and Lennard T.W. The proliferative effects of 5-androstene-3 beta,17 beta-diol and 5 alpha-dihydrotestosterone on cell cycle analysis and cell proliferation in MCF-7, T47D and MDAMB231 breast cancer cell lines. J. Steroid Biochem. Mol. Biol. 88 (2004) 37-51
3. ATAC Trialists Group. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. The Lancet 365 (2005) 60-62
4. ATAC Trialists Group. Effect of anastrozol and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 9 (2008) 45-53
5. Azzi A., Rehse P.H., Zhu D.-W., Campbell R.L., Labrie F., and Lin S.-X. Crystal structure of human estrogenic 17beta-hydroxysteroid dehydrogenase complexed with 17beta-estradiol. Nat. Struct. Biol. 3 (1996) 665-668
6. Bhatnagar A.S., Batzl C., Häusler A., Schieweck K., Lang M., and Trunet P.F. Pharmacology of non-steroidal aromatase inhibitors. In: Pasqualini J.R., and Katzenellenbogen B.S. (Eds). Hormone-Dependent Cancer (1996), Marcel Dekker, New York 155-168
7. Birrell S.N., Hall R.E., and Tilley W.D. Role of the androgen receptor in human breast cancer. J. Mammary Gland Biol. Neoplasia 3 (1998) 95-103
8. Breitling R., Krazeisen G., Möller J., and Adamski J. 17beta-hydroxysteroid dehydrogenase type 7-an ancient 3-ketosteroid reductase of cholesterogenesis. Mol. Cell. Endocrinol. 171 (2001) 199-204
9. Breton R., Housset D., Mazza C., and Fontecilla-Camps J.C. The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors. Structure 4 (1996) 905-915
10. Canadian Cancer Society (www.cancer.ca). Breast Cancer Statistics.
11. Chung H., Jung Y.M., Shin D.H., Lee J.Y., Oh M.Y., Kim H.J., Jang K.S., Jeon S.J., Son K.H., and Kong G. Anticancer effects of wogonin in both estrogen receptor-positive and -negative human breast cancer cell lines in vitro and in nude mice xenografts. Int. J. Cancer 122 (2008) 816-822
12. Ciobanu L.C., Luu-The V., Martel C., Labrie F., and Poirier D. Inhibition of estrone sulfate-induced uterine growth by potent nonestrogenic steroidal inhibitors of steroid sulfatase. Cancer Res. 63 (2003) 6442-6446
13. Couture P., Theriault C., Simard J., and Labrie F. Androgen receptor-mediated stimulation of 17 beta-hydroxysteroid dehydrogenase activity by dihydrotestosterone and medroxyprogesterone acetate in ZR-75-1 human breast cancer cells. Endocrinology 132 (1993) 179-185
14. Day J.M., Tutill H.J., Newman S.P., Purohit A., Lawrence H.R., Vicker N., Potter B.V., and Reed M.J. 17β-Hydroxysteroid dehydrogenase Type 1 and Type 2: association between mRNA expression and activity in cell lines. Mol. Cell Endocrinol. 248 (2006) 246-249
15. Day J.M., Foster P.A., Tutill H.J., Parsons M.F., Newman S.P., Chander S.K., Allan G.M., Lawrence H.R., Vicker N., Potter B.V., Reed M.J., and Purohit A. 17β-hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone-dependent breast cancer. Int. J. Cancer 122 (2008) 1931-1940
16. Dorgan J.F., Stanczyk F.Z., Longcope C., Stephenson Jr. H.E., Chang L., Miller R., Franz C., Falk R.T., and Kahle L. Relationship of serum dehydroepiandrosterone (DHEA), DHEA sulfate, and 5-androsterone-3beta, 17beta-diol to risk in postmenopausal women. Cancer Epidemiol. Biomarker Prev. 6 (1997) 177-182
17. Frotscher M., Ziegler E., Marchais-Oberwinkler S., Kruchten P., Neugebauer A., Fetzer L., Scherer C., Müller-Vieira U., Messinger J., Thole H., and Hartmann R.W. Design, Synthesis, and biological evaluation of (hydroxyphenyl) naphthalene and quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) for the treatment of estrogen-dependent diseases. J. Med. Chem. 51 (2008) 2158-2169
18. Gangloff A., Shi R., Nahoum V., and Lin S.-X. Pseudo-symmetry of C19-steroids, alternative binding orientations, and multispecificity in human estrogenic 17β-hydroxysteroid dehydrogenase. FASEB J. 17 (2003) 274-276
19. Ghosh D., Pletnev V.Z., Zhu D.W., Wawrzak Z., Duax W.L., Pangborn W., Labrie F., and Lin S.X. Structure of human 17β-Hydroxysteroid Dehydrogenase at 2.20. A resolution. Structure 3 (1995) 503-513
20. Greeve M.A., Allan R.K., Harvey J.M., and Bentel J.M. Inhibition of MCF-7 breast cancer cell proliferation by 5alpha-dihydrotestosterone: a role for p21(Cip1/Waf1). J Mol Endocrinol 32 (2004) 793-810
21. Gunnarsson C., Hellqvist E., and Stål O. 17β-Hydroxysteroid dehydrogenases involved in local oestrogen synthesis have prognostic significance in breast cancer. Brit. J. Cancer 92 (2005) 547-552
22. Hall J.M., Lee M.K., Newman B., Morrow J.E., Anderson L.A., Huey B., and King M.C. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250 (1990) 1684-1689
23. Han Q., Campbell R.L., Gangloff A., Huang Y.W., and Lin S.-X. Dehydroepiandrosterone and dihydrotestosterone recognition by human estrogenic 17beta-hydroxysteroid dehydrogenase. C-18/C-19 steroid discrimination and enzyme-induced strain. J. Biol. Chem. 275 (2000) 1105-1111
24. Hirvela, L., Johansson, N., Koskimies, P., Pentikainen, O.T., Nyronen, T., Salminen, T.A., Johnson, M.S., 2005. Novel compounds and their use in therapy. PCT WO 2005032527.
25. Huang Y.-W., Pineau I., Chang H.-J., Azzi A., Bellemare V., Laberge S., and Lin S.-X. Critical residues for the specificity toward NADH or NADPH in human estrogenic 17beta-hydroxysteroid dehydrogenase: site-directed mutagenesis designed from the three-dimensional structure of the enzyme. Mol. Endocrinol. 15 (2001) 2010-2020
26. Husen B., Huhtinen K., Saloniemi T., Messinger J., Thole H.H., and Poutanen M. Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts. Endocrinology 147 (2006) 5333-5339
27. James M.R., Skaar T.C., Lee R.Y., MacPherson A., Zwiebel J.A., Ahluwalia B.S., Ampy F., and Clarke R. Constitutive expression of the steroid sulfatase gene supports the growth of MCF-7 human breast cancer cells in vitro and in vivo. Endocrinology 142 (2001) 1497-1505
28. Jarabak J. Soluble 17beta-hydroxysteroid dehydrogenase of human placenta. Methods Enzymol. 15 (1969) 746-752
29. Jin J.Z., and Lin S.X. Human estrogenic 17beta-hydroxysteroid deshydrogenase: predominence of estrone reduction and its induction by NADPH. Biochem. Biophys. Res. Commun. 259 (1999) 489-493
30. Krazeisen A., Breitling R., Imai K., Fritz S., Möller G., and Adamski J. Determination of cDNA, gene structure and chromosomal localisation of the novel human 17beta-hydroxysteroid dehydrogenase type 7 (1). FEBS Lett. 460 (1999) 373-379
31. Labrie F. Intracrinology. Mol. Cell Endocrinol. 78 (1991) C113-C118
32. Labrie F., Luu-The V., Lin S.-X., Simard J., Labrie C., El-Alfy M., Pelletier G., and Belanger A. Intracrinology: role of the family of 17beta-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol. 25 (2000) 1-16
33. Laplante Y., Cadot C., Fournier M.A., and Poirier D. Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid deshydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone. Bioorg. Med. Chem. 16 (2008) 1849-1860
34. Lin S.-X., Yang F., Jin J.-Z., Breton R., Zhu D.-W., Luu-The V., and Labrie F. Subunit identity of the dimeric 17beta-hydroxysteroid dehydrogenase from human placenta. J. Biol. Chem. 267 (1992) 16182-16187
35. Lin S.-X., Shi R., Qiu W., Azzi A., Zhu D.-W., Al Dabbagh H., and Zhou M. Structural basis of the multispecificity demonstrated by 17β-HSD types 1 and 5. Mol. Cell. Endocrinol. 248 (2006) 38-46
36. Lipworth L., Adami H.O., Trichopoulos D., Carlstrom K., and Mantzoros C. Serum steroid hormone levels, sex hormone-binding globulin, and body mass index in the ethiology of postmenopausal breast cancer. Epidemiology 7 (1996) 96-100
37. Liu H., Zheng S., Bellemare V., Pelletier G., Labrie F., and Luu-The V. Expression and localization of estrogenic type 12 17beta-hydroxysteroid dehydrogenase in the cynomolgus monkey. BMC Biochem. 8 (2007) 2
38. Luu-The V., Tremblay P., and Labrie F. Characterization of type 12 17β-hydroxysteroid dehydrogenase responsible for estradiol formation in women. Mol. Endocrinol. 20 (2006) 437-443
39. MacIndoe J.R., Woods G., Jeffries L., and Hinkhouse M. The hydrolysis of estrone sulfate and dehydroepiandrosterone sulfate by MCF-7 human breast cancer cells. Endocrinology 123 (1988) 1281-1287
40. Messinger, J., Thole, H.-H., Husen, B., Van Steen, B.J., Schneider, G., Hulshof, J.B.E., Koskimies, P., Johansson, N., Adamski, J., 2005. Novel 17beta-hydroxysteroid dehydrogenase type 1 inhibitors. PCT WO 2005047303.
41. Miettinen M.M., Mustonen M.J.V., Poutanen M.H., Isomaa V.V., and Vihko R.K. Human 17β-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. Biochem. J. 314 (1996) 839-845
42. Mindnich R., Moller G., and Adamski J. The role of 17beta-hydroxysteroid dehydrogenases. Mol. Cell Endocrinol. 218 (2004) 7-20
43. Mindnich R., Deluca D., and Adamski J. Identification and characterization of 17β-hydroxysteroid dehydrogenases in zebra fish, Denio rerio. Mol. Cell. Endocrinol. 215 (2004) 19-30
44. Miyoshi Y., Ando A., Shiba E., Taguchi T., Tamaki Y., and Noguchi S. Involvement of up-regulation of 17beta-hydroxysteroid dehydrogenase type 1 in maintenance of intratumoral high estradiol levels in postmenopausal breast cancers. Int. J. Cancer 94 (2001) 685-689
45. Nguyen B.-L., Chetrite G., and Pasqualini J.R. Transformation of estrone and estradiol in hormone-dependent and hormone-independent human breast cancer cells. Effects of the antiestrogen ICI 164,384, danazol, and promegestone (R-5020). Breast Cancer Res. Treat. 34 (1995) 139-146
46. Nokelainen P., Peltoketo H., Vihko R., and Vihko P. Expression cloning of a novel estragenic mouse 17beta-hydroxysteroid dehydrogenase/17ketosteroid reductase (m17HSD7), previously described as a prolactin receptor-associated protein (PRAP) in rat. Mol. Endocrinol. 12 (1998) 1059-1084
47. Pasqualini J.R. The selective estrogen enzyme modulators in breast cancer: a review. Biochim. Biophys. Acta 1654 (2004) 123-143
48. Pasqualini J.R., Gelly C., Nguyen B.-L., and Vella C. Importance of estrogen sulfates in breast cancer. J. Steroid Biochem. 34 (1989) 155-163
49. Pasqualini J.R., Chetrite G., Blacker C., Feinstein M.-C., Delalonde L., Talbi M., and Maloche C. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer. J. Clin. Endocrinol. Metab. 81 (1996) 1460-1464
50. Peltoketo H., Luu-The V., Simard J., and Adamski J. 17beta-hydroxysteroid dehydrogenase (HSD)/17ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. J. Mol. Endocrinol. 23 (1999) 1-11
51. Poirier D. Inhibitors of 17beta-hydroxysteroid dehydrogenase. Curr. Med. Chem. 10 (2003) 453-477
52. Poirier D., Boivin R.P., Tremblay M.R., Berube M., Qiu W., and Lin S.-X. Estradiol hybrid compounds designed to inhibit type 1 17β-hydroxysteroid dehydrogenase. J. Med. Chem. 48 (2005) 8134-8147
53. Poirier D., Chang H.-K., Azzi A., Boivin R., Lin P., and Estrone S.-X. Estradiol C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase. Mol. Cell. Endocrinol. 248 (2006) 236-238
54. Poulin R., and Labrie F. Stimulation of cell proliferation and estrogen response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line. Cancer Res. 46 (1986) 4933-4937
55. Puranen T., Poutanen M., Ghosh D., Vihko P., and Vihko R. Characterization of structural and functional properties of human 17β-Hydroxysteroid Hehydrogenase type 1 using recombinant enzymes and site-directed mutagenis. Mol. Endocrinol. 11 (1997) 77-86
56. Qiu W., Campbell R.L., Gangloff A., Dupuis P., Boivin P., Tremblay M.R., Poirier D., and Lin S.-X. A concerted, rational design of 17beta-hydroxysteroid dehydrogenase inhibitors: estradiol-adenosine hybrid with high affinity. FASEB J. 16 (2002) 1829-1931
57. Redondo-Müller M.A., Stevanovic-Walker M., Barker S., Puddefoot J.R., and Vinson G.P. Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor. Endocr. Relat. Cancer 15 (2008) 277-288
58. Salhab M., Reed M.J., Al Sarakbi W., Jiang W.G., and Mokbel K. The role of aromatase and 17-β-hydroxysteroid dehydrogenase type 1 mRNA expression in predicting the clinical outcome of human breast cancer. Breast Cancer Res. Treat. 99 (2006) 155-162
59. Santner S.J., Feil P.D., and Santen R.J. In situ estrogen production via estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J. Clin. Endocrinol. Metab. 59 (1984) 29-33
60. Sasano H., Suzushi T., Nakata N., and Mariya T. New development in intracrinology of breast carcinoma. Breast Cancer 13 (2006) 129-136
61. Schuster D., Nashev L.G., Kirchmair J., Laggner C., Wobler G., Langer T., and Odermatt A. Discovery of nonsteroidal 17beta-hydroxysteroid dehydrogenase 1 inhibitors by pharmacophore-based screening of virtual compound libraries. J. Med. Chem. 51 (2008) 4188-4199
62. Shan L., Wang S., Korotcov A., Sridhar R., and Wang P.C. Bioluminescent animal models of human breast cancer for tumor biomass evaluation and metastasis detection. Ethn. Dis. Spring. 18 2 Suppl. 2 (2008) S2-65-S2-69
63. Shi R., and Lin S.-X. Cofactor hydrogen bonding onto the protein main chain is conserved in the short-chain dehydrogenase/reductase family and contributes to nicotinamide orientation. J. Biol. Chem. 279 (2004) 16778-16785
64. Song D., Liu G., Luu-The V., Zhao D., Wang L., Zhang H., Xueling G., Li S., Désy L., Labrie F., and Pelletier G. Expression of aromatase and 17β-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer: an immunocytochemical study. J. Steroid Biochem. Mol. Biol. 101 (2006) 136-144
65. Stanway S.J., Purohit A., Woo L.W.L., Sufi S., Vigushin D., Ward R., Wilson R.H., Stanczyk F.Z., Dobbs N., Kulinskaya E., Elliott M., Potter B.V., Reed M.J., and Coombes R.C. Phase I study of STX64 (667 COUMATE) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin. Cancer Res. 12 (2006) 1585-1592
66. Thomas D.B. Do hormones cause breast cancer?. Cancer 53 (1984) 595-604
67. Vermeulen A., Deslypere J.P., and Paridaens R. Steroid dynamics in the normal and carcinomatous mammary gland. J. Steroid Biochem. 25 (1986) 799-802
68. Vihko R., and Apter D. Endogenous steroids in the pathophysiology of breast cancer. Crit. Rev. Oncol. Hematol. 9 (1989) 1-16
69. Vihko P., Herrala A., Härkönen P., Isomaa V., Kaija H., Kurkela R., and Pulkka A. Control of cell proliferation by steroids: the role of 17HSDs. Mol. Cell. Endocrinol. 248 (2006) 141-148
70. Yue W., Wang J.-P., Hamilton C.J., Demers L.M., and Santen R.J. In situ aromatization enhances breast tumor estradiol levels and cellular proliferation. Cancer Res. 58 (1998) 927-932
71. +. J. Mol. Biol. 234 (1993) 242-244